SEC Comment Letter 0000000000-24-006251 to T2 Biosystems, Inc. (TTOO) (CIK 0001492674)
T2 Biosystems, Inc. (TTOO) (CIK 0001492674)
Date: May 30, 2024 · CIK: 0001492674 · Accession: 0000000000-24-006251
AI Filing Summary & Sentiment
File numbers found in text: 333-279740
Letter
United States securities and exchange commission logo May 30, 2024 John Sperzel President, Chief Executive Officer and Chairman of the Board T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 Re:T2 Biosystems, Inc. Registration Statement on Form S-3 Filed May 28, 2024 File No. 333-279740 Dear John Sperzel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Conlon Danberg at 202-551-4466 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Johan Brigham, Esq.
Show Raw Text
United States securities and exchange commission logo
May 30, 2024
John Sperzel
President, Chief Executive Officer and Chairman of the Board
T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, MA 02421
Re:T2 Biosystems, Inc.
Registration Statement on Form S-3
Filed May 28, 2024
File No. 333-279740
Dear John Sperzel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Conlon Danberg at 202-551-4466 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Johan Brigham, Esq.